{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:41:06Z","timestamp":1788716466719,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>In diesem \u00f6sterreichweiten Consensus Statement sind die Empfehlungen zum Umgang mit latenter Tuberkulose bei Therapie mit biologischen und \u201etargeted synthetic\u201c DMARDs zusammengefasst. Die wesentlichen Fragen bez\u00fcglich des Screenings und pr\u00e4ventiver Therapie wurden von Expertinnen und Experten aus den Fachbereichen Rheumatologie, Pneumologie, Infektiologie, Dermatologie und Gastroenterologie auf Basis der vorhandenen Daten diskutiert und dann in einer Abstimmung zum gemeinsamen Konsens gebracht. Dabei wurde auch differenziert auf die unterschiedlichen Therapien eingegangen, und klare Empfehlungen wurden formuliert.<\/jats:p>","DOI":"10.1007\/s00393-022-01274-6","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T09:19:38Z","timestamp":1667812778000},"page":"163-174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Consensus Statement der \u00d6sterreichischen Gesellschaften f\u00fcr Rheumatologie und Rehabilitation, Pneumologie, Infektiologie, Dermatologie und Gastroenterologie zum Umgang mit latenter Tuberkulose bei Therapien mit biologischen oder \u201etargeted synthetic\u201c DMARDs (\u201edisease modifying antirheumatic drugs\u201c)","National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic DMARDS (disease modifying antirheumatic drugs)"],"prefix":"10.1007","volume":"82","author":[{"given":"Eva","family":"Rath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Duftner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentine","family":"Moazedi-Furst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herwig","family":"Pieringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Puchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Flick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut J. F.","family":"Salzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Skvara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Moschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Feurstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Sautner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"1274_CR1","unstructured":"Consensus Statement 2011 \u00d6sterreichische \u00c4rztezeitung. https:\/\/infektiologie.co.at\/wp-content\/uploads\/2017\/08\/cs-tbc_u_biologika.pdf. Zugegriffen: 10.10.2022"},{"key":"1274_CR2","unstructured":"WHO-Global Tuberculosis Report 2020. https:\/\/www.who.int\/publications\/i\/item\/9789240013131. Zugegriffen: 10.10.2022"},{"key":"1274_CR3","unstructured":"https:\/\/www.ages.at\/themen\/krankheitserreger\/tuberkulose-tbc\/. Zugegriffen: 10.10.2022"},{"key":"1274_CR4","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","year":"2018","unstructured":"WHO (Hrsg) (2018) Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. World Health Organization, Geneva"},{"issue":"10","key":"1274_CR5","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.150051","volume":"42","author":"RF van Vollenhoven","year":"2015","unstructured":"van Vollenhoven\u00a0RF, Fleischmann\u00a0RM, Furst\u00a0DE, Lacey\u00a0S, Lehane\u00a0PB (2015) Longterm safety of Rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J\u00a0Rheumatol 42(10):1761\u20131766. https:\/\/doi.org\/10.3899\/jrheum.150051","journal-title":"J Rheumatol"},{"key":"1274_CR6","doi-asserted-by":"publisher","first-page":"1759720X2093011","DOI":"10.1177\/1759720X20930116","volume":"12","author":"G Evangelatos","year":"2020","unstructured":"Evangelatos\u00a0G, Koulouri\u00a0V, Iliopoulos\u00a0A, Fragoulis\u00a0GE (2020) Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskelet Dis 12:1759720X20930116","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"Suppl 2","key":"1274_CR7","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","volume":"24","author":"M Mikulska","year":"2018","unstructured":"Mikulska\u00a0M, Lanini\u00a0S, Gudiol\u00a0C, Drgona\u00a0L, Ippolito\u00a0G, Fern\u00e1ndez-Ruiz\u00a0M, Salzberger\u00a0B, ESCMID Study Group for Infections in Compromised Hosts (ESGICH) (2018) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect 24(Suppl 2):S71\u2013S82. https:\/\/doi.org\/10.1016\/j.cmi.2018.02.003","journal-title":"Clin Microbiol Infect"},{"issue":"15","key":"1274_CR8","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane\u00a0J, Gershon\u00a0S, Wise\u00a0RP, Mirabile-Levens\u00a0E, Kasznica\u00a0J, Schwieterman\u00a0WD, Siegel\u00a0JN, Braun\u00a0MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N\u00a0Engl J Med 345(15):1098\u20131104. https:\/\/doi.org\/10.1056\/NEJMoa011110","journal-title":"N Engl J Med"},{"issue":"sup1","key":"1274_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","volume":"15","author":"S Minozzi","year":"2016","unstructured":"Minozzi\u00a0S, Bonovas\u00a0S, Lytras\u00a0T, Pecoraro\u00a0V, Gonz\u00e1lez-Lorenzo\u00a0M, Judina Bastiampillai\u00a0A, Gabrielli\u00a0EM, Lonati\u00a0AC, Moja\u00a0L, Cinquini\u00a0M, Marino\u00a0V, Matucci\u00a0A, Milano\u00a0GM, Tocci\u00a0G, Scarpa\u00a0R, Goletti\u00a0D, Cantini\u00a0F (2016) Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a\u00a0systematic review and meta-analysis. Expert Opin Drug Saf 15(sup1):11\u201334. https:\/\/doi.org\/10.1080\/14740338.2016.1240783","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 2","key":"1274_CR10","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","volume":"24","author":"JW Baddley","year":"2018","unstructured":"Baddley\u00a0JW, Cantini\u00a0F, Goletti\u00a0D, G\u00f3mez-Reino\u00a0JJ, Mylonakis\u00a0E, San-Juan\u00a0R, Fern\u00e1ndez-Ruiz\u00a0M, Torre-Cisneros\u00a0J, ESCMID Study Group for Infections in Compromised Hosts (ESGICH) (2018) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor\u2011\u03b1 agents). Clin Microbiol Infect 24(Suppl 2):S10\u2013S20. https:\/\/doi.org\/10.1016\/j.cmi.2017.12.025","journal-title":"Clin Microbiol Infect"},{"key":"1274_CR11","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/ard.2009.118935","volume":"69","author":"WG Dixon","year":"2010","unstructured":"Dixon\u00a0WG, Hyrich\u00a0KL, Watson\u00a0KD, Lunt\u00a0M, Galloway\u00a0J, Ustianowski\u00a0A et al (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69:522\u2013528","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"1274_CR12","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","volume":"24","author":"KL Winthrop","year":"2018","unstructured":"Winthrop\u00a0KL, Mariette\u00a0X, Silva\u00a0JT, Benamu\u00a0E, Calabrese\u00a0LH, Dumusc\u00a0A, Smolen\u00a0JS, Aguado\u00a0JM, Fern\u00e1ndez-Ruiz\u00a0M, ESCMID Study Group for Infections in Compromised Hosts (ESGICH) (2018) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 24(Suppl 2):S21\u2013S40. https:\/\/doi.org\/10.1016\/j.cmi.2018.02.002","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"1274_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","volume":"14","author":"F Cantini","year":"2015","unstructured":"Cantini\u00a0F, Nannini\u00a0C, Niccoli\u00a0L, Iannone\u00a0F, Delogu\u00a0G, Garlaschi\u00a0G, Sanduzzi\u00a0A, Matucci\u00a0A, Prignano\u00a0F, Conversano\u00a0M, Goletti\u00a0D (2015) Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. SAFEBIO (Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy). Autoimmun Rev 14(6):503\u2013509. https:\/\/doi.org\/10.1016\/j.autrev.2015.01.011","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1274_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","volume":"14","author":"L Cantarini","year":"2015","unstructured":"Cantarini\u00a0L, Lopalco\u00a0G, Caso\u00a0F, Costa\u00a0L, Iannone\u00a0F, Lapadula\u00a0G, Anelli\u00a0MG, Franceschini\u00a0R, Menicacci\u00a0C, Galeazzi\u00a0M, Selmi\u00a0C, Rigante\u00a0D (2015) Effectiveness and tuberculosis-related safety profile of interleukin\u20111 blocking agents in the management of Beh\u00e7et\u2019s disease. Autoimmun Rev 14(1):1\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2014.08.008","journal-title":"Autoimmun Rev"},{"issue":"5","key":"1274_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/14740338.2019.1612872","volume":"18","author":"F Cantini","year":"2019","unstructured":"Cantini\u00a0F, Niccoli\u00a0L, Capone\u00a0A, Petrone\u00a0L, Goletti\u00a0D (2019) Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf 18(5):415\u2013425. https:\/\/doi.org\/10.1080\/14740338.2019.1612872","journal-title":"Expert Opin Drug Saf"},{"key":"1274_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/MD.0b013e3181fdd832","volume":"89","author":"L de Beaucoudrey","year":"2010","unstructured":"de Beaucoudrey\u00a0L, Samarina\u00a0A, Bustamante\u00a0J, Cobat\u00a0A, Boisson-Dupuis\u00a0S, Feinberg\u00a0J et al (2010) Revisiting human IL-12Rb1 deficiency: a\u00a0survey of 141\u00a0patients from 30\u00a0countries. Medicine 89:381\u2013402","journal-title":"Medicine"},{"issue":"7","key":"1274_CR17","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/art.40861","volume":"71","author":"DJ Wallace","year":"2019","unstructured":"Wallace\u00a0DJ, Ginzler\u00a0EM, Merrill\u00a0JT, Furie\u00a0RA, Stohl\u00a0W, Chatham\u00a0WW, Weinstein\u00a0A, McKay\u00a0JD, McCune\u00a0WJ, Petri\u00a0M, Fettiplace\u00a0J, Roth\u00a0DA, Ji\u00a0B, Heath\u00a0A (2019) Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus. Arthritis Rheumatol 71(7):1125\u20131134","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1274_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jdv.14015","volume":"31","author":"K Reich","year":"2017","unstructured":"Reich\u00a0K, Gooderham\u00a0M, Green\u00a0L, Bewley\u00a0A, Zhang\u00a0Z, Khanskaya\u00a0I, Day\u00a0RM, Goncalves\u00a0J, Shah\u00a0K, Piguet\u00a0V, Soung\u00a0J (2017) The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a\u00a0phase IIIb, randomized, placebo-controlled trial (LIBERATE). J\u00a0Eur Acad Dermatol Venereol 31(3):507\u2013517. https:\/\/doi.org\/10.1111\/jdv.14015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1274_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","volume":"157","author":"BE Elewski","year":"2021","unstructured":"Elewski\u00a0BE, Baddley\u00a0JW, Deodhar\u00a0AA, Magrey\u00a0M, Rich\u00a0PA, Soriano\u00a0ER, Soung\u00a0J, Bao\u00a0W, Keininger\u00a0D, Marfo\u00a0K, Patekar\u00a0M, Sharma\u00a0A, Shete\u00a0A, Lebwohl\u00a0MG (2021) Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. JAMA Dermatol 157(1):43\u201351. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3257 (Erratum in: JAMA Dermatol. 2021 Jan 1;157(1):124)","journal-title":"JAMA Dermatol"},{"issue":"Suppl 1","key":"1274_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000501989","volume":"11","author":"S Ribero","year":"2019","unstructured":"Ribero\u00a0S, Licciardello\u00a0M, Quaglino\u00a0P, Dapavo\u00a0P (2019) Efficacy and safety of secukinumab in patients with plaque psoriasis and latent tuberculosis. Case Rep Dermatol 11(Suppl 1):23\u201328. https:\/\/doi.org\/10.1159\/000501989","journal-title":"Case Rep Dermatol"},{"issue":"30","key":"1274_CR21","doi-asserted-by":"publisher","first-page":"eaau6759","DOI":"10.1126\/sciimmunol.aau6759","volume":"3","author":"JG Markle","year":"2019","unstructured":"Markle\u00a0JG, Mart\u013anez-Barricarte\u00a0RCS, Ma\u00a0CS, Deenick\u00a0EK, Ram\u00edrez-Alejo\u00a0N, Mele\u00a0F, Latorre\u00a0D, Alireza Mahdaviani\u00a0S, Aytekin\u00a0C, Mansouri\u00a0D, Bryant\u00a0V, Jabot-Hanin\u00a0F, Deswarte\u00a0C, Nieto-Patl\u00e1n\u00a0A, Surace\u00a0L, Kerner\u00a0G, Itan\u00a0Y, Jovic\u00a0S, Avery\u00a0DT, Wong\u00a0N, Rao\u00a0G, Patin\u00a0E, Okada\u00a0S, Bigio\u00a0B, Boisson\u00a0B, Rapaport\u00a0F, Seeleuthner\u00a0Y, Schmidt\u00a0M, Ikinciogullari\u00a0A, Dogu\u00a0F, Tanir\u00a0G, Tabarsi\u00a0P, Bloursaz\u00a0MRJKJ, Avneet Heer, Kong\u00a0X\u2011F, Migaud\u00a0M, Lazarov\u00a0T, Geissmann\u00a0F, Fleckenstein\u00a0B, Lindestam Arlehamn\u00a0C, Sette\u00a0A, Puel\u00a0A, Emile\u00a0J\u2011F, van de Vosse\u00a0E, Lluis Quintana-Murci Di Santo\u00a0JP, Abel\u00a0L, Boisson-Dupuis\u00a0S, Bustamante\u00a0J, Tangye\u00a0SG, Sallusto\u00a0F, Casanova\u00a0J\u2011L (2019) Human IFN\u2011\u03b3 immunity to mycobacteria is governed by both IL-12 and IL-23. Sci Immunol 3(30):eaau6759. https:\/\/doi.org\/10.1126\/sciimmunol.aau6759","journal-title":"Sci Immunol"},{"issue":"4","key":"1274_CR22","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/jdv.16866","volume":"35","author":"M Nogueira","year":"2021","unstructured":"Nogueira\u00a0M, Warren\u00a0RB, Torres\u00a0T (2021) Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis\u2014time for a\u00a0paradigm change. J\u00a0Eur Acad Dermatol Venereol 35(4):824\u2013834","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1274_CR23","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop\u00a0KL, Park\u00a0SH, Gul\u00a0A, Cardiel\u00a0MH, Gomez-Reino\u00a0JJ, Tanaka\u00a0Y, Kwok\u00a0K, Lukic\u00a0T, Mortensen\u00a0E, Ponce de Leon\u00a0D, Riese\u00a0R, Valdez\u00a0H (2016) Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis 75(6):1133\u20131138","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1274_CR24","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/14740338.2020.1774550","volume":"19","author":"F Cantini","year":"2020","unstructured":"Cantini\u00a0F, Blandizzi\u00a0C, Niccoli\u00a0L, Petrone\u00a0L, Goletti\u00a0D (2020) Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. Expert Opin Drug Saf 19(7):861\u2013872","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"1274_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt\u00a0J, Lee\u00a0EB, Curtis\u00a0JR, Silverfield\u00a0J, Terry\u00a0K, Soma\u00a0K, Mojcik\u00a0C, DeMasi\u00a0R, Strengholt\u00a0S, Kwok\u00a0K, Lazariciu\u00a0I, Wang\u00a0L, Cohen\u00a0S (2019) Safety and efficacy of tofacitinib for up to 9.5\u00a0years in the treatment of rheumatoid arthritis: final results of a\u00a0global, open-label, long-term extension study. Arthritis Res Ther 21(1):89. https:\/\/doi.org\/10.1186\/s13075-019-1866-2","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"1274_CR26","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/jbmr.3119","volume":"32","author":"NB Watts","year":"2017","unstructured":"Watts\u00a0NB, Brown\u00a0JP, Papapoulos\u00a0S, Lewiecki\u00a0EM, Kendler\u00a0DL, Dakin\u00a0P, Wagman\u00a0RB, Wang\u00a0A, Daizadeh\u00a0NS, Smith\u00a0S, Bone\u00a0HG (2017) Safety observations with 3 years of denosumab exposure: comparison between subjects who received Denosumab during the randomized FREEDOM trial and subjects who crossed over to Denosumab during the FREEDOM extension. J\u00a0Bone\u00a0Miner Res 32(7):1481\u20131485. https:\/\/doi.org\/10.1002\/jbmr.3119","journal-title":"J Bone Miner Res"},{"issue":"5","key":"1274_CR27","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/1744-9987.12788","volume":"23","author":"A Torres-Ortiz","year":"2019","unstructured":"Torres-Ortiz\u00a0A, Acharya\u00a0P, Cheungpasitporn\u00a0W (2019) Successful treatment of tuberculosis-associated hypercalcemia with denosumab in a\u00a0patient with acute kidney injury. Ther Apher Dial 23(5):484\u2013485","journal-title":"Ther Apher Dial"},{"issue":"11","key":"1274_CR28","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1007\/s10067-020-04948-1","volume":"39","author":"S Kaveh","year":"2020","unstructured":"Kaveh\u00a0S, Hosseinifard\u00a0H, Ghadimi\u00a0N, Vojdanian\u00a0M, Aryankhesal\u00a0A (2020) Efficacy and safety of Romosozumab in treatment for low bone mineral density: a\u00a0systematic review and meta-analysis. Clin Rheumatol 39(11):3261\u20133276. https:\/\/doi.org\/10.1007\/s10067-020-04948-1","journal-title":"Clin Rheumatol"},{"issue":"5","key":"1274_CR29","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","volume":"66","author":"JF Colombel","year":"2017","unstructured":"Colombel\u00a0JF, Sands\u00a0BE, Rutgeerts\u00a0P, Sandborn\u00a0W, Danese\u00a0S, D\u2019Haens\u00a0G, Panaccione\u00a0R, Loftus\u00a0EV Jr, Sankoh\u00a0S, Fox\u00a0I, Parikh\u00a0A, Milch\u00a0C, Abhyankar\u00a0B, Feagan\u00a0BG (2017) The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease. Gut 66(5):839\u2013851","journal-title":"Gut"},{"issue":"7","key":"1274_CR30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne\u00a0DRW, Merkel\u00a0PA, Schall\u00a0TJ, Bekker\u00a0P, ADVOCATE Study Group (2021) Avacopan for the treatment of ANCA-associated vasculitis. N\u00a0Engl J Med 384(7):599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2023386","journal-title":"N Engl J Med"},{"issue":"26","key":"1274_CR31","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro\u00a0M, Corren\u00a0J, Pavord\u00a0ID, Maspero\u00a0J, Wenzel\u00a0S, Rabe\u00a0KF, Busse\u00a0WW, Ford\u00a0L, Sher\u00a0L, FitzGerald\u00a0JM, Katelaris\u00a0C, Tohda\u00a0Y, Zhang\u00a0B, Staudinger\u00a0H, Pirozzi\u00a0G, Amin\u00a0N, Ruddy\u00a0M, Akinlade\u00a0B, Khan\u00a0A, Chao\u00a0J, Martincova\u00a0R, Graham\u00a0NMH, Hamilton\u00a0JD, Swanson\u00a0BN, Stahl\u00a0N, Yancopoulos\u00a0GD, Teper\u00a0A (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N\u00a0Engl J Med 378(26):2486\u20132496. https:\/\/doi.org\/10.1056\/NEJMoa1804092","journal-title":"N Engl J Med"},{"issue":"7","key":"1274_CR32","doi-asserted-by":"publisher","first-page":"e0235488","DOI":"10.1371\/journal.pone.0235488","volume":"15","author":"V Taneja","year":"2020","unstructured":"Taneja\u00a0V, Kalra\u00a0P, Goel\u00a0M, Khilnani\u00a0GC, Saini\u00a0V, Prasad\u00a0GBKS, Gupta\u00a0UD, Prasad\u00a0KH (2020) Impact and prognosis of the expression of IFN\u2011\u03b1 among tuberculosis patients. PLoS ONE 15(7):e235488. https:\/\/doi.org\/10.1371\/journal.pone.0235488","journal-title":"PLoS ONE"},{"issue":"8","key":"1274_CR33","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3389\/fimmu.2017.01633","volume":"27","author":"ML Donovan","year":"2017","unstructured":"Donovan\u00a0ML, Schultz\u00a0TE, Duke\u00a0TJ, Blumenthal\u00a0A (2017) Type I Interferons in the pathogenesis of tuberculosis: molecular drivers and immunological consequences. Front Immunol 27(8):1633. https:\/\/doi.org\/10.3389\/fimmu.2017.01633","journal-title":"Front Immunol"},{"key":"1274_CR34","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1186\/s12879-019-4654-3","volume":"19","author":"J Wang","year":"2019","unstructured":"Wang\u00a0J, Hussain\u00a0T, Zhang\u00a0K et\u00a0al (2019) Inhibition of type I interferon signaling abrogates early mycobacterium bovis infection. BMC Infect Dis 19:1031. https:\/\/doi.org\/10.1186\/s12879-019-4654-3","journal-title":"BMC Infect Dis"},{"issue":"1","key":"1274_CR35","doi-asserted-by":"publisher","first-page":"e000464","DOI":"10.1136\/lupus-2020-000464","volume":"8","author":"R Tummala","year":"2021","unstructured":"Tummala\u00a0R, Abreu\u00a0G, Pineda\u00a0L, Michaels\u00a0MA, Kalyani\u00a0RN, Furie\u00a0RA, Morand\u00a0EF (2021) Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med 8(1):e464. https:\/\/doi.org\/10.1136\/lupus-2020-000464","journal-title":"Lupus Sci Med"},{"issue":"1","key":"1274_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","volume":"69","author":"TR Sterling","year":"2020","unstructured":"Sterling\u00a0TR, Njie\u00a0G, Zenner\u00a0D, Cohn\u00a0DL, Reves\u00a0R, Ahmed\u00a0A, Menzies\u00a0D, Horsburgh\u00a0CR Jr, Crane\u00a0CM, Burgos\u00a0M, LoBue\u00a0P, Winston\u00a0CA, Belknap\u00a0R (2020) Guidelines for the treatment of latent tuberculosis infection: recommendations from the national tuberculosis controllers association and CDC. MMWR Recomm Rep 69(1):1\u201311. https:\/\/doi.org\/10.15585\/mmwr.rr6901a1","journal-title":"MMWR Recomm Rep"},{"key":"1274_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1055\/s-0043-105954","volume":"71","author":"T Schaberg","year":"2017","unstructured":"Schaberg\u00a0T et al (2017) 2Sk-Leitlinie: Tuberkulose im Erwachsenenalter. Pneumologie 71:325\u2013397. https:\/\/doi.org\/10.1055\/s-0043-105954","journal-title":"Pneumologie"},{"issue":"7","key":"1274_CR38","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel\u00a0L, Bathon\u00a0JM, England\u00a0BR, St Clair\u00a0EW, Arayssi\u00a0T, Carandang\u00a0K, Deane\u00a0KD, Genovese\u00a0M, Huston\u00a0KK, Kerr\u00a0G, Kremer\u00a0J, Nakamura\u00a0MC, Russell\u00a0LA, Singh\u00a0JA, Smith\u00a0BJ, Sparks\u00a0JA, Venkatachalam\u00a0S, Weinblatt\u00a0ME, Al-Gibbawi\u00a0M, Baker\u00a0JF, Barbour\u00a0KE, Barton\u00a0JL, Cappelli\u00a0L, Chamseddine\u00a0F, George\u00a0M, Johnson\u00a0SR, Kahale\u00a0L, Karam\u00a0BS, Khamis\u00a0AM, Navarro-Mill\u00e1n\u00a0I, Mirza\u00a0R, Schwab\u00a0P, Singh\u00a0N, Turgunbaev\u00a0M, Turner\u00a0AS, Yaacoub\u00a0S, Akl\u00a0EA (2021) American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 73(7):1108\u20131123. https:\/\/doi.org\/10.1002\/art.41752","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1274_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12955-017-0754-1","volume":"15","author":"A Darzi","year":"2017","unstructured":"Darzi\u00a0A, Harfouche\u00a0M, Arayssi\u00a0T, Alemadi\u00a0S, Alnaqbi\u00a0KA, Badsha\u00a0H, Al Balushi\u00a0F, Elzorkany\u00a0B, Halabi\u00a0H, Hamoudeh\u00a0M, Hazer\u00a0W, Masri\u00a0B, Omair\u00a0MA, Uthman\u00a0I, Ziade\u00a0N, Singh\u00a0JA, Christiansen\u00a0R, Tugwell\u00a0P, Sch\u00fcnemann\u00a0HJ, Akl\u00a0EA (2017) Adaptation of the 2015 American College of Rheumatology treatment guideline for rheumatoid arthritis for the Eastern Mediterranean Region: an exemplar of the GRADE Adolopment. Health Qual Life Outcomes 15(1):183. https:\/\/doi.org\/10.1186\/s12955-017-0754-1 (Erratum in: Health Qual Life Outcomes. 2017 Oct 26;15(1):214)","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"1274_CR40","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen\u00a0JS, Landew\u00e9\u00a0RBM, Bijlsma\u00a0JWJ, Burmester\u00a0GR, Dougados\u00a0M, Kerschbaumer\u00a0A, McInnes\u00a0IB, Sepriano\u00a0A, van Vollenhoven\u00a0RF, de Wit\u00a0M, Aletaha\u00a0D, Aringer\u00a0M, Askling\u00a0J, Balsa\u00a0A, Boers\u00a0M, den Broeder\u00a0AA, Buch\u00a0MH, Buttgereit\u00a0F, Caporali\u00a0R, Cardiel\u00a0MH, De Cock\u00a0D, Codreanu\u00a0C, Cutolo\u00a0M, Edwards\u00a0CJ, van Eijk-Hustings\u00a0Y, Emery\u00a0P, Finckh\u00a0A, Gossec\u00a0L, Gottenberg\u00a0JE, Hetland\u00a0ML, Huizinga\u00a0TWJ, Koloumas\u00a0M, Li\u00a0Z, Mariette\u00a0X, M\u00fcller-Ladner\u00a0U, Mysler\u00a0EF, da Silva\u00a0JAP, Po\u00f3r\u00a0G, Pope\u00a0JE, Rubbert-Roth\u00a0A, Ruyssen-Witrand\u00a0A, Saag\u00a0KG, Strangfeld\u00a0A, Takeuchi\u00a0T, Voshaar\u00a0M, Westhovens\u00a0R, van der Heijde\u00a0D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1274_CR41","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen\u00a0JS, Landew\u00e9\u00a0R, Breedveld\u00a0FC, Buch\u00a0M, Burmester\u00a0G, Dougados\u00a0M, Emery\u00a0P, Gaujoux-Viala\u00a0C, Gossec\u00a0L, Nam\u00a0J, Ramiro\u00a0S, Winthrop\u00a0K, de Wit\u00a0M, Aletaha\u00a0D, Betteridge\u00a0N, Bijlsma\u00a0JW, Boers\u00a0M, Buttgereit\u00a0F, Combe\u00a0B, Cutolo\u00a0M, Damjanov\u00a0N, Hazes\u00a0JM, Kouloumas\u00a0M, Kvien\u00a0TK, Mariette\u00a0X, Pavelka\u00a0K, van Riel\u00a0PL, Rubbert-Roth\u00a0A, Scholte-Voshaar\u00a0M, Scott\u00a0DL, Sokka-Isler\u00a0T, Wong\u00a0JB, van der Heijde\u00a0D (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492\u2013509. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204573","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1274_CR42","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","volume":"58","author":"CR Holroyd","year":"2019","unstructured":"Holroyd\u00a0CR, Seth\u00a0R, Bukhari\u00a0M, Malaviya\u00a0A, Holmes\u00a0C, Curtis\u00a0E, Chan\u00a0C, Yusuf\u00a0MA, Litwic\u00a0A, Smolen\u00a0S, Topliffe\u00a0J, Bennett\u00a0S, Humphreys\u00a0J, Green\u00a0M, Ledingham\u00a0J (2019) The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Baillieres Clin Rheumatol 58(2):e3\u2013e42. https:\/\/doi.org\/10.1093\/rheumatology\/key208 (Erratum in: Rheumatology (Oxford). 2019 Feb 1;58(2):372)","journal-title":"Baillieres Clin Rheumatol"},{"issue":"7","key":"1274_CR43","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/ddg.14507_g","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast A et al (2021) Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm \u2013 Teil 1: Therapieziele und Therapieempfehlungen. J\u00a0Dtsch Dermatol Ges 19(7):1092\u20131117. https:\/\/doi.org\/10.1111\/ddg.14507_g","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"1274_CR44","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1183\/09031936.00151309","volume":"36","author":"CBE Chee","year":"2010","unstructured":"Chee\u00a0CBE, Khinmar\u00a0KW, Gan\u00a0SH, Barkham\u00a0TM, Koh\u00a0CK, Shen\u00a0L, Wang\u00a0YT (2010) Tuberculosis treatment effect on T\u2011cell interferon\u2011\u03b3 responses to Mycobacterium tuberculosis-specific antigens. Eur Respir\u00a0J 36:355\u2013361. https:\/\/doi.org\/10.1183\/09031936.00151309","journal-title":"Eur Respir J"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01274-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-022-01274-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01274-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T13:07:04Z","timestamp":1677762424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-022-01274-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1274"],"URL":"https:\/\/doi.org\/10.1007\/s00393-022-01274-6","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"assertion":[{"value":"15 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"E.\u00a0Rath, M.\u00a0Bonelli, C.\u00a0Duftner, J.\u00a0Gruber, P.\u00a0Mandl, F.\u00a0Moazedi-Furst, H.\u00a0Pieringer, R.\u00a0Puchner, H.\u00a0Flick, H.J.F.\u00a0Salzer, G.\u00a0Weiss, S.\u00a0Winkler, H.\u00a0Skvara, A.\u00a0Moschen, H.\u00a0Hofer, J.\u00a0Feurstein und J.\u00a0Sautner geben an, keinen Interessenkonflikt bei der Erstellung dieses Consensus zu haben. Das Projekt wurde ohne jedes Sponsoring geplant und ausgef\u00fchrt.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}